These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16673599)

  • 1. Urinary prostate specific antigen: is the clinical use likely?
    Pejcic T; Hadzi-Djokic J; Acimovic M; Topuzovic C; Milkovic B; Janjic A
    Acta Chir Iugosl; 2005; 52(4):69-74. PubMed ID: 16673599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary PSA in monitoring of patients with prostate cancer.
    Pejcić T; Dimitrijević V; Hadzi-Djokić J
    Acta Chir Iugosl; 2012; 59(1):57-60. PubMed ID: 22924305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?
    Pejcic TP; Tulic CDz; Lalic NV; Glisic BD; Ignjatovic SD; Markovic BB; Hadzi-Djokic JB
    Can J Urol; 2013 Apr; 20(2):6707-13. PubMed ID: 23587511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
    Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
    Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary PSA level and relative tumor volume after prostate biopsy.
    Pejcić T; Hadzi-Djokić J; Marković B; Dragićević D; Glisić B; Lalić N; Aćimović M; Dzamić Z; Radosavljevic R
    Acta Chir Iugosl; 2009; 56(2):17-21. PubMed ID: 19780325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density.
    Benson MC; McMahon DJ; Cooner WH; Olsson CA
    World J Urol; 1993; 11(4):206-13. PubMed ID: 7508785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
    Wolff JM; Boeckmann W; Borchers H; Handt S; Reineke T; Jakse G
    Urol Int; 1996; 57(3):170-4. PubMed ID: 8912446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen in urine.
    Breul J; Pickl U; Hartung R
    Eur Urol; 1994; 26(1):18-21. PubMed ID: 7523129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
    Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasensitive prostate specific antigen assay following laparoscopic radical prostatectomy--an outcome measure for defining the learning curve.
    Viney R; Gommersall L; Zeif J; Hayne D; Shah ZH; Doherty A
    Ann R Coll Surg Engl; 2009 Jul; 91(5):399-403. PubMed ID: 19409146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate biopsy in patients with long-term use of indwelling bladder catheter: what is the rationale?
    Antunes AA; Barbosa JA; Reis ST; Guariero MS; Fukushima JT; Dall'oglio MF; Freire Gde C; Lucon AM; Leite KR; Srougi M
    Urol Oncol; 2012 Sep; 30(5):620-3. PubMed ID: 20933446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage.
    Scattoni V; Roscigno M; Raber M; Montorsi F; Da Pozzo L; Guazzoni G; Freschi M; Rigatti P
    Eur Urol; 2003 Oct; 44(4):407-14. PubMed ID: 14499673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands.
    Iwakiri J; Granbois K; Wehner N; Graves HC; Stamey T
    J Urol; 1993 Apr; 149(4):783-6. PubMed ID: 7681118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.
    Marley GM; Miller MC; Kattan MW; Zhao G; Patton KP; Vessella RL; Wright GL; Schellhammer PF; Veltri RW
    Urology; 1996 Dec; 48(6A Suppl):16-22. PubMed ID: 8973695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.
    Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
    Urol Int; 1998; 60(3):152-5. PubMed ID: 9644784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.